PHAT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
74.3M
+27.4%
58.3M
+1.2%
57.6M
+16.3%
49.5M
+25.3%
39.5M
Cost of Revenue
15.1M
+25.8%
12.0M
+56.9%
7.6M
+23.6%
6.2M
+22.9%
5.0M
Gross Profit
59.2M
+27.8%
46.3M
-7.3%
49.9M
+15.3%
43.3M
+25.7%
34.5M
Operating Expenses
63.1M
+2.2%
61.8M
+10.6%
55.9M
-4.6%
58.6M
-37.9%
94.4M
R&D
7.8M
+0.5%
7.8M
+3.7%
7.5M
+6.6%
7.0M
-22.6%
9.1M
SG&A
55.3M
+2.4%
54.0M
+11.7%
48.4M
-6.2%
51.6M
-39.6%
85.3M
Operating Income
-3965000
+74.4%
-15477000
-161.1%
-5928000
+61.2%
-15271000
+74.5%
-59924000
EBITDA
-3851000
+74.9%
-15367000
-164.9%
-5800000
+61.6%
-15115000
+74.7%
-59752000
Net Income
-17582000
+42.1%
-30369000
-43.6%
-21148000
+29.4%
-29973000
+60.5%
-75810000
EPS (Basic)
$-0.21
+43.2%
$-0.37
-27.6%
$-0.29
+29.3%
$-0.41
+61.0%
$-1.05
EPS (Diluted)
$-0.21
+43.2%
$-0.37
-27.6%
$-0.29
+29.3%
$-0.41
+61.0%
$-1.05
Shares (Diluted)
83.7M
+2.1%
82.1M
+11.1%
73.8M
+0.6%
73.4M
+1.3%
72.5M
Phathom Pharmaceuticals (PHAT) โ€” Financials